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Background and aims: Bacille-Calmette-Guerin (BCG), prepared from attenuated live Mycobacterium
bovis, modulates atherosclerosis development as currently explained by immunomodulatory mecha-
nisms. However, whether BCG is pro- or anti-atherogenic remains inconclusive as the effect of BCG on
cholesterol metabolism, the main driver of atherosclerosis development, has remained underexposed in
previous studies. Therefore, we aimed to elucidate the effect of BCG on cholesterol metabolism in
addition to inﬂammation and atherosclerosis development in APOE*3-Leiden.CETP mice, a well-
established model of human-like lipoprotein metabolism.
Methods: Hyperlipidemic APOE*3-Leiden.CETP mice were fed a Western-type diet containing 0.1%
cholesterol and were terminated 6 weeks after a single intravenous injection with BCG (0.75 mg;
5  106 CFU).
Results: BCG-treated mice exhibited hepatic mycobacterial infection and hepatomegaly. The enlarged
liver (þ53%, p ¼ 0.001) coincided with severe immune cell inﬁltration and a higher cholesterol content
(þ31%, p ¼ 0.03). Moreover, BCG reduced plasma total cholesterol levels (34%, p ¼ 0.003), which was
conﬁned to reduced nonHDL-cholesterol levels (36%, p ¼ 0.002). This was due to accelerated plasma
clearance of cholesterol from intravenously injected [14C]cholesteryl oleate-labelled VLDL-like particles
(t½ 41%, p ¼ 0.002) as a result of elevated hepatic uptake (þ25%, p ¼ 0.05) as well as reduced intestinal
cholestanol and plant sterol absorption (up to 37%, p ¼ 0.003). Ultimately, BCG decreased foam cell
formation of peritoneal macrophages (18%, p ¼ 0.02) and delayed atherosclerotic lesion progression in
the aortic root of the heart. BCG tended to decrease atherosclerotic lesion area (59%, p ¼ 0.08) and
reduced lesion severity.
Conclusions: BCG reduces plasma nonHDL-cholesterol levels and delays atherosclerotic lesion formation
in hyperlipidemic mice.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).ndocrinology, Post zone C7Q,
RC Leiden, The Netherlands.
am).
r Ireland Ltd. This is an open acces1. Introduction
Cardiovascular disease is the leading cause of death in Western
countries, and atherosclerosis is the pathology underlying most
cardiovascular events. The main risk factor for the development ofs article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
A.D. van Dam et al. / Atherosclerosis 251 (2016) 6e14 7atherosclerosis is hypercholesterolemia, as excess cholesterol ini-
tiates foam cell formation in the arterial wall. Subsequently, in-
ﬂammatory processes including recruitment of innate and adaptive
immune cells contribute to further development of the plaque,
which may eventually lead to plaque rupture and/or vessel occlu-
sion [1]. A variety of bacteria and viruses [2], but also bacterial
components such as lipopolysaccharide [3], have been suggested to
be implicated in atherosclerosis development. In this respect,
Bacille-Calmette-Guerin (BCG), prepared from attenuated live
Mycobacterium bovis and the only licensed vaccine against tuber-
culosis [4], is of special interest since BCG is used worldwide for
vaccination.
Interestingly, animal studies have shown that BCG modulates
atherosclerosis development. However, the data on whether BCG
reduces or enhances atherosclerosis development are conﬂicting.
BCG injection in rabbits in which plasma cholesterol levels were
maintained constant (i.e. by individual adjustment of the percent-
age of cholesterol in the diet) increased lymphocyte and monocyte
activation and hence atherosclerosis development [5]. In contrast,
repeated injections of killed BCG reduced atherosclerosis in LDL
receptor-knockout (Ldlr/) and apolipoprotein E-knockout (Apoe/
) mice, but did not signiﬁcantly modulate plasma cholesterol
levels. The reduced atherosclerosis development was accompanied
by enhanced circulating IL-10 levels and reduced serum levels of
pro-inﬂammatory cytokines [6]. Although these pro- and anti-
atherogenic effects have been attributed to immunomodulatory
effects of BCG, the effect of BCG on the metabolism of cholesterol,
the main driver of atherosclerosis development, has remained
underexposed.
Therefore, in the current study we aimed to elucidate the effect
of BCG on cholesterol metabolism and atherosclerosis development
in APOE*3-Leiden.CETP (E3L.CETP) transgenic mice. These mice have
a humanized lipoprotein proﬁle due to expression of human
cholesterol ester transfer protein (CETP), which transfers choles-
teryl esters fromHDL to LDL and VLDL in exchange for triglycerides,
and a mutation of the human APOE*3 gene, which attenuates
clearance of cholesterol-enriched lipoprotein remnants without
abrogating the apoE-LDLR clearance pathway [7e9]. We show that
BCG markedly reduces plasma cholesterol levels as a result of
accelerated hepatic uptake of cholesterol-enriched lipoprotein
remnants and reduced intestinal cholesterol absorption. Finally,
BCG reduces foam cell formation and delays atherosclerotic plaque
formation.
2. Materials and methods
An expanded Materials and Methods section is available in the
Supplemental Materials and Methods. Female E3L.CETP mice,
10e12 weeks of age, were fed a Western-type diet containing 0.1%
cholesterol (WTD; Hope Farms, The Netherlands) and received an
intravenous injection with a human dose of Bacille-Calmette-
Guerin (BCG) vaccine SSI (0.75 mg; 5  106 CFU in 100 mL PBS; SSI
Denmark) [10]. Body weight and composition were determined as
well as plasma (i.e. total cholesterol (TC), HDL-cholesterol, nonHDL-
cholesterol and triglycerides (TG)) and liver (i.e. TC, TG and phos-
pholipids) lipids. Six weeks after the injection, plasma decay and
organ uptake was measured of intravenously injected VLDL-like
TG-rich particles that were labelled with glycerol tri[3H]oleate
(TO) and [14C]cholesteryl oleate (CO). Mice were sacriﬁced, upon
which several organs were harvested for assessment of mycobac-
terial presence. White blood cells were analysed by ﬂow cytometry
and peritoneal macrophages, splenocytes and bone marrow cells
were isolated for ex vivo stimulation and subsequent determination
of cytokine secretion and oxidized LDL uptake. Histology, choles-
terol and non-sterol extraction and analysis, quantitative RT-PCRand Western Blots were performed on liver samples. Atheroscle-
rotic lesion area and composition were also histologically assessed
in the aortic root of the heart. Groups were compared with a two-
tailed unpaired Student’s t-test, unless stated otherwise.
3. Results
3.1. BCG induces mycobacterial infection in hyperlipidemic mice
E3L.CETP mice were fed a Western-type diet containing 0.1%
cholesterol (WTD) and received a single intravenous BCG injection.
After six weeks, blood and various organs were cultured to inves-
tigate whether viable BCG was still present. Blood of BCG-treated
mice tested negative for mycobacteria. However, livers, spleens
and bone marrow of BCG-treated mice were positive for myco-
bacteria (Suppl. Fig. 1 and data not shown), indicating ongoing
infection.
3.2. BCG induces hepatic inﬂammation
Since BCG induced hepatic mycobacterial infection and the liver
plays a key role in lipid metabolism, we further studied the livers of
the BCG-treated animals. Liver weight was increased in BCG-
treated mice (þ53%, Fig. 1A). In these livers, severe leukocyte
inﬁltration (Fig. 1B) and accumulation of F4/80-positive cells
(Fig. 1C) was observed. This coincided with increased expression of
inﬂammatory markers including F4/80 and Inf as well as the T cell
markers Cd3, Cd4 and Cd8 (Fig. 1D). Besides hepatomegaly, BCG-
treated mice also exhibited an enlarged spleen (þ149%, Fig. 1A).
3.3. BCG induces overall immune activation
Given the inﬂammatory state of the liver, we assessed the effect
of BCG on circulating white blood cells by ﬂow cytometry. Within
the CD45þ white blood cells, BCG did not signiﬁcantly affect the
relative monocyte or granulocyte content (Suppl. Fig. 2A, B), but did
reduce the percentage of B cells (33%, Suppl. Fig. 2C). The per-
centage of total T cells remained similar upon BCG vaccination
(Suppl. Fig. 2D), but BCG increased T helper cells (þ11%, Fig. 2A)
without altering cytotoxic T cells (Fig. 2D). Activation of T helper
cells was not affected by BCG (Fig. 2B), but the memory T helper
cells tended to be higher (þ59%, Fig. 2C). More pronounced effects
on activation and memory were found within the cytotoxic T cells,
as BCG induced both activation (þ204%, Fig. 2E) and memory
(þ84%, Fig. 2F) of cytotoxic T cells. Overall, these ﬁndings suggest
that BCG induces activation of circulating immune cells.
To determine the inﬂammatory status of tissue macrophages,
we performed ex vivo stimulation of peritoneal macrophages,
splenocytes and bonemarrow-derivedmacrophages andmeasured
cytokine secretion. BCG increased the number of macrophages in
the peritoneal cavity (þ37%, Fig. 2G). Even after correcting for the
number of cells, the peritoneal macrophages of BCG-treated mice
produced more inﬂammatory cytokines upon LPS stimulation than
macrophages from untreated animals (i.e. TNF, IL-1b; Fig. 2HeK),
suggesting an increased innate inﬂammatory phenotype.
Splenocytes from BCG-treated mice also produced more in-
ﬂammatory cytokines upon LPS stimulation (i.e. IL-6, TNF, IL-10;
Suppl. Fig. 2EeG), conﬁrming the inﬂammatory phenotype. Inter-
estingly, upon adaptive immune response stimulation (i.e. with C.
Albicans) splenocytes also produced more IFNg (Suppl. Fig. 2H),
suggesting that BCG activates CD4þ and CD8þ T cells in the spleen,
in line with our observations on circulating cells.
Bone marrow cell counts were lower in mice treated with BCG
(28%, Fig. 2L). After adjusting for the number of cells, bone
marrow-derivedmacrophages (BMDMs) from BCG treatedmice did
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Fig. 1. BCG induces hepatic inﬂammation. E3L.CETP mice fed a WTD were treated with PBS or BCG (0.75 mg; 5  106 CFU; i.v.). Upon sacriﬁce after 6 weeks, liver and spleen were
collected and weighed (A). Haematoxylin and Eosin (B) and F4/80 staining (C) of liver sections was performed. Representative pictures are shown. The relative content of F4/80
positive cells was quantiﬁed (C). Hepatic mRNA expression of the indicated inﬂammatory genes was determined (D). Values represent means ± SEM (n ¼ 6). **p < 0.01, ***p < 0.001
vs. PBS.
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the reduced bone marrow cell counts reﬂect hematopoietic stem
and progenitor cell exhaustion. LPS stimulation of BMDMs did not
reveal alterations in cytokine production (data not shown). Taken
together, BCG infection resulted in increased overall immune
activation.3.4. BCG lowers body fat but increases liver lipid content
To assess the effect of BCG on the metabolic phenotype of
E3L.CETP mice, body weight and composition were measured over
the 6-week period after BCG administration. Total body weight
(Fig. 3A) and food intake (Fig. 3B) were not affected by BCG. After 6
weeks, lean body mass remained unaffected (Fig. 3C), but fat mass
tended to be lower in BCG-treated animals (32%, Fig. 3D), which
was corroborated by a reducedweight of the gonadal white fat pads
(36%, Fig. 3E). In line with the increase in liver weight, BCG-
treated mice exhibited increased liver lipid content (i.e. TG,
cholesterol and phospholipids), although the increase in TG content
did not reach statistical signiﬁcance (Fig. 3F).
BCG lowers plasma cholesterol by accelerating hepatic uptake of
cholesterol-enriched lipoprotein remnants and reducing intestinal
cholesterol absorption.
As hypercholesterolemia is the main risk factor for atheroscle-
rosis development, we studied the effect of BCG on plasma lipid
levels. BCG tended to decrease plasma TG levels after 6 weeks
(34%, Fig. 4A), and consistently reduced plasma total cholesterol
(TC) levels during the study (34% at the endpoint, Fig. 4B) when
compared to the PBS-treated group. This reduction in TC was
conﬁned to lowering of the nonHDL-cholesterol fraction (Fig. 4C).
To investigate whether the reduced plasma TC levels were due to
increased clearance of lipoprotein remnant cholesterol, we
assessed the plasma clearance and organ uptake of glycerol tri[3H]
oleate (TO)- and [14C]cholesteryl oleate (CO)-double-labelled VLDL-
like particles in vivo. Plasma clearance of [3H]TO was comparablebetween the groups (Fig. 4D, t½ ¼ 3.0 vs. 3.4 min, p ¼ 0.09), and no
obvious effects on organ uptake of 3H-activity were found apart
from an increased uptake by the spleen (þ109%, Fig. 4E). In contrast,
BCG markedly accelerated plasma clearance of [14C]CO (Fig. 4F,
t½ ¼ 5.0 vs. 8.5 min, p ¼ 0.002), mainly due to increased uptake of
[14C]CO by the liver (þ25%, p ¼ 0.05) and to a lesser extent also by
the spleen (þ214%, Fig. 4G). The increase in liver and spleen weight
are key to this increased [14C]CO-uptake, as uptake of [14C]CO by
liver and spleen did not differ when expressed per gram organ
(data not shown). These data support the notion that BCG reduces
plasma TC levels by enhancing hepatic uptake of cholesterol-
enriched lipoprotein remnants.
Besides increased cholesterol clearance, reduced hepatic
cholesterol synthesis or intestinal cholesterol absorption could
underlie the reduced plasma cholesterol levels. To assess whether
BCG affects hepatic cholesterol synthesis, we determined the
cholesterol precursors lanosterol, desmosterol and lathosterol in
the liver (Fig. 4H). The ratios of lanosterol and desmosterol to total
cholesterol were increased (þ53 and þ 79%) upon BCG treatment,
whereas the ratio of lathosterol to cholesterol remained un-
changed. This suggests increased rather than decreased hepatic
cholesterol synthesis. As measures of intestinal cholesterol ab-
sorption, we measured cholestanol, campesterol and sitosterol in
the liver (Fig. 4I). The ratios of cholestanol and campesterol to total
cholesterol were decreased (28% and 37). These data indicate
that BCG reduces intestinal cholesterol absorption.
We next assessed gene expression and protein content in the
liver, upon BCG treatment. BCG did not affect genes involved in
cholesterol metabolism, including Ldlr, Apob and Hmgcoar, nor
LDLR and SR-BI protein content (data not shown).3.5. BCG delays atherosclerosis development
Since BCG markedly increased immune activation, but lowered
plasma cholesterol levels, we investigated the effects of BCG on
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Fig. 2. BCG increases immune activation. E3L.CETP mice fed a WTD were treated with PBS or BCG (0.75 mg; 5  106 CFU; i.v.). After 6 weeks, blood, peritoneal macrophages and
bone marrow were collected. Within the CD3þ T cell fraction, percentage of CD4þ (A) and CD8þ (D) cells were determined. Within the CD4þ and CD8þ T cell fractions, percentages of
activated T cells (CD44þCD25þ; B, E) and memory T cells (CD44þCD25; C, F) were determined. Peritoneal macrophages were counted (G) and stimulated with LPS. Production of IL-
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A.D. van Dam et al. / Atherosclerosis 251 (2016) 6e14 9foam cell formation and atherosclerosis development. BCG reduced
the ex vivo uptake of oxLDL by peritoneal macrophages (18%,
Fig. 5A) and BMDMs (27%, Fig. 5B), suggesting reduced foam cell
formation and an overall anti-atherogenic phenotype of macro-
phages after BCG treatment.
We therefore determined atherosclerotic lesion area of the le-
sions in the aortic root of the heart 6 weeks after BCG adminis-
tration. Interestingly, BCG tended to reduce atherosclerotic lesion
area throughout the aortic root (Fig. 5C, D) as well as the mean
atherosclerotic lesion area (59%, Fig. 5E). Although lesion severity
was generally mild, BCG still induced a shift towards a reducedlesion severity. In addition, the number of non-diseased segments
tended to be higher after BCG treatment (þ155%, Fig. 5G). In line
with the reduced lesion severity, BCG increased the macrophage
content of the lesions (þ43%, Fig. 5H). Collagen content (Fig. 5I) and
lesion stability (ratio collagen/macrophage area, Fig. 5J) were not
affected by BCG.When only type 3 lesions were compared between
groups, the macrophage content and lesion stability were unaf-
fected (data not shown), indicating that BCG did not induce a more
inﬂammatory or unstable phenotype of the lesions. Together, our
ﬁndings indicate that BCG administration decreases plasma
cholesterol levels and delays atherosclerosis development.
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BCG has been shown to modulate atherosclerosis development
through immunomodulatory mechanisms [5,6], but its effect on
cholesterol metabolism, the main determinant of atherosclerosis,
has not been investigated before. In the current study, we show that
BCG administration in hyperlipidemic E3L.CETP mice induced an
overall inﬂammatory phenotype, as shown by hepatic infection and
inﬂammation, and activation of circulating T cells as well as peri-
toneal macrophages and splenocytes. Furthermore, BCG markedly
decreased plasma nonHDL-cholesterol levels by enhancing hepatic
clearance of cholesterol and reduced foam cell formation ex vivo. As
a result of these anti-atherogenic characteristics, BCG delayed
atherosclerosis progression and reduced lesion severity.
We found BCG to be present in the liver, spleen and bone
marrow 6 weeks after administration, indicating that the myco-
bacterium disseminated to these organs. In humans, dissemination
of BCG can occur upon vaccination [11e13] and disseminated BCG
infections can manifest in bladder cancer patients as a side effect of
intravesical treatment with BCG [14]. Our ﬁnding that the liver and
spleen were enlarged in the BCG-treated group has also been
observed in humans upon disseminated BCG infection [13,15] andextrapulmonary tuberculosis [16,17]. Together, these reports indi-
cate that our study can be translated to the human situation.
Besides increased immune activation, we observed a large
reduction of plasma nonHDL-cholesterol levels upon BCG admin-
istration, which was accompanied by elevated hepatic uptake of
circulating cholesterol-enriched lipoprotein remnants and reduced
intestinal cholesterol absorption. Since plasma HDL-cholesterol nor
hepatic SR-BI content was altered, it seems unlikely that BCG in-
ﬂuences reverse cholesterol transport. An underlying mechanism
for the reduced plasma nonHDL-cholesterol levels could be that
accumulated immune cells [18] as well as mycobacteria [19e22],
both of which we detected in the liver, are responsible for the
increased hepatic lipoprotein remnant uptake. Immune cells use
lipids as an energy source and cholesterol is indispensable as a
membrane component for cell growth, proliferation andmembrane
remodelling [18,23,24]. Mycobacteria use host cholesterol for entry
into macrophages and as a source of carbon and energy, as they
cannot synthesize cholesterol themselves [19,20,25]. Therefore,
host cholesterol is essential for the persistence of infection [19e21].
ForMycobacterium leprae, which also infects macrophages and uses
host cholesterol for survival, it was recently shown that infected
macrophages take up LDL by upregulation of LDLR [26].
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Fig. 5. BCG decreases atherosclerosis development. E3L.CETPmice fed a WTD were treated with PBS or BCG (0.75 mg; 5  106 CFU; i.v.). After 6 weeks, peritoneal macrophages (A)
and bone marrow-derived macrophages (B) were incubated with oxLDL and uptake was measured. Hearts were collected and slides of the valve area of the aortic root of were
stained with haematoxylinephloxineesaffron (C). Atherosclerotic lesion area as a function of distance was determined (D) and the mean lesion area was calculated from the four
cross-sections from D (E). Lesions were categorized according to lesion severity (F) and the percentage of non-diseased segments was scored (G). The macrophage (H) and collagen
(I) content of the lesions was determined, and the stability index (collagen/macrophage content of the lesions) was calculated (J). Values represent means ± SEM (n ¼ 6). *p < 0.05
vs. PBS.
A.D. van Dam et al. / Atherosclerosis 251 (2016) 6e1412Furthermore, Ldlr expression was shown to be upregulated in
caseous human pulmonary tuberculosis granulomas [27], sup-
porting the possibility that upregulation of LDLR speciﬁcally in
infected tissue macrophages underlies the increased cholesterol
uptake in our study. An additional cause of the reduced plasma
nonHDL-cholesterol levels is the reduced intestinal cholesterolabsorption as evidenced by reduced cholestanol and plant sterol
levels in the liver. Intestinal absorption can be dysregulated by
systemic or intra-abdominal inﬂammation, which is also observed
in coeliac disease, Crohn’s disease [28] and cystic ﬁbrosis patients
[29,30]. Evidently, BCG infection and subsequent inﬂammation also
lead to reduced cholesterol absorption.
A.D. van Dam et al. / Atherosclerosis 251 (2016) 6e14 13Several pieces of evidence suggest that mycobacteria modulate
lipid metabolism in humans as well. For instance, cholesterol levels
in Nigerian adults with tuberculosis are lower when compared to
healthy controls [31]. Deniz et al. [32] also show that serum total
cholesterol, HDL-cholesterol and LDL-cholesterol concentrations
are lower in patients with pulmonary tuberculosis. Moreover,
Mycobacterium tuberculosis uses fatty acids from host triglycerides
as a lipid source [33] and tuberculosis patients exhibit lower serum
medium-chain fatty acids [34]. Unfortunately, to our knowledge, no
data exist on plasma cholesterol levels in patients with dissemi-
nated BCG infection.
Ultimately, BCG tended to reduce atherosclerotic lesion area by
more than half, and delayed the onset and progression of athero-
sclerosis evidenced by 1) the increased number of non-diseased
segments; 2) the higher percentage of mild type 1 lesions; 3) the
increased macrophage content of the lesions, indicative for mild
type 1 and 2 lesions. Although the latter could also point to a more
inﬂammatory phenotype of the lesions, this was contradicted by
the fact that the macrophage content and lesion stability index
within type 3 lesions only did not differ between the groups. Pre-
vious studies that investigated the effect of BCG on atherosclerosis
focussed on the immunomodulatory effects of BCG and were not
properly designed to investigate the effect of BCG on cholesterol
metabolism. In one study performed in rabbits, plasma cholesterol
level of each individual rabbit was maintained at a speciﬁc level by
adjusting the cholesterol content in the diet [5], excluding the
possibility to investigate the effects of BCG on cholesterol meta-
bolism. Ovchinnikova et al. [6] studied the effect of BCG that was
killed by extensive freeze-drying on atherosclerosis and did not
ﬁnd changes in plasma cholesterol levels upon BCG treatment in
Apoe/mice and Ldlr/mice. However, even though Apoe/ and
Ldlr/mice are the most widely used atherosclerosis models, they
lack a functional hepatic ApoE-LDLR axis, the predominant route by
which cholesterol-enriched lipoprotein remnants are cleared from
the circulation [9]. Based on our study in E3L.CETP mice, with a
functional ApoE-LDLR pathway for lipoprotein remnant clearance,
we conclude that the cholesterol lowering effect of BCG overrules
the effect of immune activation during the development of
atherosclerosis, resulting in delayed atherosclerotic plaque
formation.
Carotid atherosclerosis is increased in patients with chronic
infections and interestingly, the atherosclerosis risk is highest in
those with the most prominent inﬂammatory response, indicating
that systemic inﬂammation contributes to atherosclerosis [35].
However, Giral et al. [36] compared hypercholesterolemic patients
with and without a history of tuberculosis and found that past
tuberculosis is not associated with atherosclerosis development.
Whether mycobacterial infection has beneﬁcial effects on athero-
sclerosis in humans related to a reduction in plasma cholesterol
remains to be investigated.
In conclusion, our data demonstrate that BCG infection lowers
plasma nonHDL-cholesterol levels by accelerating hepatic uptake of
cholesterol-enriched lipoprotein remnants and reducing intestinal
absorption of dietary cholesterol. Furthermore, BCG delays
atherosclerotic plaque formation despite increased immune acti-
vation, most likely due to lowering of nonHDL-cholesterol. Because
BCG is used as a vaccine for tuberculosis worldwide, the effect of
BCG on atherosclerosis in humans is an interesting ﬁeld of future
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